Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott awaits FDA's decision on consent decree

This article was originally published in Clinica

Executive Summary

Abbott is expecting the FDA to respond to the company's reply concerning the consent decree - which involved the halting of sales of numerous in vitro diagnostic products after the company failed to implement measures demanded by various warning letters (see Clinica No 883, p 1) - by mid- to late-April. The agency's reply will determine whether Abbott's diagnostic facilities are in conformity with the Quality System Regulation. Abbott's US hospital product sales were up by 6% to $674 million in the quarter. The company attributes the growth to demand for its IV solutions and equipment business. Worldwide diagnostics sales fell by 4% to $679 million. The diagnostics business was hit by foreign exchange effects, which reduced sales by 3.4%. The company expects sales in this unit to improve over the next few quarters because of a recent contract with the American Red Cross and the expected strengthening of its glucose monitoring business. In addition, depending on the outcome of the consent decree, Abbott plans to launch numerous immunoassay products.

You may also be interested in...



Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.

Topics

UsernamePublicRestriction

Register

MT066011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel